Skip to search formSkip to main contentSkip to account menu

GS-5816

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

velpatasvir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The Discovery of Velpatasvir (GS-5816): The Potent Pan-Genotypic Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimens Epclusa and Vosevi®
The initial approval of the single-tablet regimen (STR) Harvoni®, containing the hepatitis C virus (HCV) nonstructural 5A protein… 
2017
2017
Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects
ABSTRACT Preclinical characterization of velpatasvir (VEL; GS-5816), an inhibitor of the hepatitis C virus (HCV) NS5A protein… 
Highly Cited
2016
Highly Cited
2016
Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein
ABSTRACT Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor… 
Highly Cited
2015
Highly Cited
2015
A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus
GS‐5816 is an inhibitor of the hepatitis C virus (HCV) NS5A protein that has demonstrated pan‐genotypic activity and a high… 
2015
2015
P0712 : The pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment
2015
2015
P0893 : Resistance analysis of treatment-experienced genotype 1 and 3 HCV infected patients treated with sofosbuvir in combination with GS-5816 +/− ribavirin for 12 weeks
2015
2015
Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study
2014
2014
O111 SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1–6 HCV INFECTION
2014
2014
P742 THE PHARMACOKINETICS OF GS-5816, A PAN-GENOTYPIC HCV NS5A INHIBITOR, IN HCV-UNINFECTED SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT
Highly Cited
2013
Highly Cited
2013
1191 GS-5816, A SECOND GENERATION HCV NS5A INHIBITOR WITH POTENT ANTIVIRAL ACTIVITY, BROAD GENOTYPIC COVERAGE AND A HIGH RESISTANCE BARRIER
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)